S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Stock market today: World shares mostly lower as Congress averts a US government shutdown
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Bank of Japan survey shows manufacturers optimistic about economy
Federal student loan payments are starting again. Here's what you need to know
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Sam Bankman-Fried must now convince a jury that the former crypto king was not a crook
Facing increasing pressure from customers, some miners are switching to renewable energy
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Grant program for Black women entrepreneurs blocked by federal appeals court
The death toll in a collapsed gold mine in Zimbabwe expected to rise to 13, vice president says
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Stock market today: World shares mostly lower as Congress averts a US government shutdown
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Bank of Japan survey shows manufacturers optimistic about economy
Federal student loan payments are starting again. Here's what you need to know
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Sam Bankman-Fried must now convince a jury that the former crypto king was not a crook
Facing increasing pressure from customers, some miners are switching to renewable energy
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Grant program for Black women entrepreneurs blocked by federal appeals court
The death toll in a collapsed gold mine in Zimbabwe expected to rise to 13, vice president says
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Stock market today: World shares mostly lower as Congress averts a US government shutdown
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Bank of Japan survey shows manufacturers optimistic about economy
Federal student loan payments are starting again. Here's what you need to know
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Sam Bankman-Fried must now convince a jury that the former crypto king was not a crook
Facing increasing pressure from customers, some miners are switching to renewable energy
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Grant program for Black women entrepreneurs blocked by federal appeals court
The death toll in a collapsed gold mine in Zimbabwe expected to rise to 13, vice president says
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Stock market today: World shares mostly lower as Congress averts a US government shutdown
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Bank of Japan survey shows manufacturers optimistic about economy
Federal student loan payments are starting again. Here's what you need to know
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Sam Bankman-Fried must now convince a jury that the former crypto king was not a crook
Facing increasing pressure from customers, some miners are switching to renewable energy
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Grant program for Black women entrepreneurs blocked by federal appeals court
The death toll in a collapsed gold mine in Zimbabwe expected to rise to 13, vice president says
NASDAQ:CCXI

ChemoCentryx (CCXI) Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$51.99
$51.99
50-Day Range
$51.66
$51.99
52-Week Range
$14.95
$52.00
Volume
113 shs
Average Volume
1.68 million shs
Market Capitalization
$3.71 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

CCXI stock logo

About ChemoCentryx (NASDAQ:CCXI) Stock

ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis. The company also develops TAVNEOS for the treatment of patients with severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy, and lupus nephritis. In addition, it develops CCX559, an orally administered inhibitor for programmed death protein 1/programmed death-ligand 1 for the treatment of various cancers; and CCX507, an orally administered inhibitor of the chemokine receptor known as CCR9, which has completed Phase I clinical trial for the treatment of inflammatory bowel disease. Further, the company has early-stage drug candidates that targets Th17 driven diseases and CCR6. ChemoCentryx, Inc. was incorporated in 1996 and is headquartered in San Carlos, California.


CCXI Stock News Headlines

AMGEN SUCCESSFULLY COMPLETES ACQUISITION OF CHEMOCENTRYX
Gold Could Be Heading for Record Highs - But How to Play It?
According to FX Empire, the gold forecast is now bullish, with support for a $3,000 target in 2024. The big question is how to play it. Some investors are discovering a unique gold investment alternative that sidesteps the major issues with gold mining stocks or physical gold.
How is This "Hidden Gem" Thriving in a Turbulent Market?
While Wall Street flounders and giants like Amazon & Microsoft lay off thousands... One overlooked company has been quietly achieving over 400% growth. How? By buying, building, and scaling a portfolio of promising brands in high-margin, recession-resistant verticals.
ChemoCentryx (NASDAQ: CCXI)
Biotech Valuations Remain In a Slump - TheStreet
Amgen CEO Sees Tougher Sleddin - GuruFocus.com
See More Headlines
Receive CCXI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ChemoCentryx and its competitors with MarketBeat's FREE daily newsletter.

CCXI Company Calendar

Last Earnings
11/08/2021
Today
10/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:CCXI
CUSIP
16383L10
Employees
178
Year Founded
N/A

Profitability

Net Income
$-131,760,000.00
Net Margins
-357.01%
Pretax Margin
-357.01%

Debt

Sales & Book Value

Annual Sales
$32.22 million
Book Value
$4.09 per share

Miscellaneous

Free Float
65,433,000
Market Cap
$3.71 billion
Optionable
Optionable
Beta
1.22
Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Dr. Thomas J. Schall Ph.D. (Age 63)
    Founder, Pres, CEO & Chairman
    Comp: $1.21M
  • Ms. Susan M. Kanaya (Age 59)
    Exec. VP, Chief Financial & Admin. Officer, Sec. and Director
    Comp: $845.04k
  • Mr. Tausif  ButtMr. Tausif Butt (Age 56)
    Exec. VP & COO
    Comp: $1.01M
  • Dr. Rita I. Jain M.D. (Age 59)
    Exec. VP, Chief Medical Officer & Exec. Employee Director
    Comp: $670.7k
  • Dr. Markus J. Cappel Ph.D. (Age 61)
    Chief Bus. Officer & Treasurer
    Comp: $643.58k
  • Ms. Yi Ching Yau (Age 46)
    Sr. VP of Fin. & Principal Accounting Officer
  • Mr. William S. Slattery
    VP of Investor Relations & Corp. Communications
  • Ms. Kari E. Leetch
    Sr. VP of HR
  • Dr. Sangita Ghosh Ph.D.
    Sr. VP of Technical Operations













CCXI Stock - Frequently Asked Questions

How were ChemoCentryx's earnings last quarter?

ChemoCentryx, Inc. (NASDAQ:CCXI) released its quarterly earnings data on Monday, November, 8th. The biopharmaceutical company reported ($0.32) earnings per share for the quarter, topping the consensus estimate of ($0.45) by $0.13. The biopharmaceutical company had revenue of $17.74 million for the quarter, compared to analyst estimates of $14.70 million. ChemoCentryx had a negative net margin of 357.01% and a negative trailing twelve-month return on equity of 48.52%. During the same period in the previous year, the business earned ($0.35) EPS.

What is Thomas J. Schall's approval rating as ChemoCentryx's CEO?

21 employees have rated ChemoCentryx Chief Executive Officer Thomas J. Schall on Glassdoor.com. Thomas J. Schall has an approval rating of 58% among the company's employees. This puts Thomas J. Schall in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 44.0% of employees surveyed would recommend working at ChemoCentryx to a friend.

What other stocks do shareholders of ChemoCentryx own?
What is ChemoCentryx's stock symbol?

ChemoCentryx trades on the NASDAQ under the ticker symbol "CCXI."

What is ChemoCentryx's stock price today?

One share of CCXI stock can currently be purchased for approximately $51.99.

How much money does ChemoCentryx make?

ChemoCentryx (NASDAQ:CCXI) has a market capitalization of $3.71 billion and generates $32.22 million in revenue each year. The biopharmaceutical company earns $-131,760,000.00 in net income (profit) each year or ($1.89) on an earnings per share basis.

How many employees does ChemoCentryx have?

The company employs 178 workers across the globe.

How can I contact ChemoCentryx?

ChemoCentryx's mailing address is 850 MAUDE AVENUE, MOUNTAIN VIEW CA, 94043. The official website for the company is www.chemocentryx.com. The biopharmaceutical company can be reached via phone at (650) 210-2900, via email at investor@chemocentryx.com, or via fax at 650-210-2910.

This page (NASDAQ:CCXI) was last updated on 10/2/2023 by MarketBeat.com Staff

My Account -